Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
AD Outcomes Improved With Lebrikizumab and Topical Steroids AD Outcomes Improved With Lebrikizumab and Topical Steroids
The ADhere study compared responses at 16 weeks to the investigational biologic and topical corticosteroids vs topical corticosteroids alone in adults and adolescents with moderate to severe AD.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - January 13, 2023 Category: Pediatrics Tags: Dermatology News Source Type: news
What to Know About Infusion Therapy for IBD
The human gastrointestinal tract can be a hostile place for visitors. It’s filled with digestive acids and microorganisms that rapidly break down swallowed bits of food, and it can be just as rough on non-food molecules. That includes some of the latest drugs for the treatment of inflammatory bowel disease (IBD). “Some medications that target the immune system don’t work if they’re swallowed because your gut would digest them like a piece of steak,” says Dr. Gilaad Kaplan, a gastroenterologist, IBD researcher, and professor of medicine at the University of Calgary in Canada. “You have to...
Source: TIME: Health - January 10, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Source Type: news
JAK Inhibitor Promising for Polymyalgia Rheumatica
(MedPage Today) -- Tofacitinib (Xeljanz) appeared highly effective against polymyalgia rheumatica (PMR) in a small single-arm trial, researchers said, suggesting another potential alternative to long-term corticosteroids.
Among 14 patients in... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - January 9, 2023 Category: Rheumatology Source Type: news
In Giant Cell Arteritis, Hospital Admission Is Bad News
(MedPage Today) -- One-third of patients admitted with giant cell arteritis (GCA) were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 29, 2022 Category: Cardiology Source Type: news
FDA approves Roche ’s Actemra for the treatment of COVID-19 in hospitalised adults
Actemra is the first FDA-approved monoclonal antibody to treat COVID-19Since the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra worldwideActemra is approved for this use in more than 30 countries for the treatment of COVID-19Basel, 21 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ® (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalised adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasi...
Source: Roche Media News - December 21, 2022 Category: Pharmaceuticals Source Type: news
End of year message from Cochrane's CEO, Catherine Spencer
Dear Cochrane Colleagues, Members and Supporters, Thank you to everyone across our community for your dedication and commitment to Cochrane during 2022. The last few years have at times felt tumultuous, both due to Covid and world events, but also because of the changes we are making to ensure that Cochrane is fit for a future that meets our vision of aworld of better health for all people, where decisions about health and care are informed by high-quality evidence. We are well on our way to creating an evolved impact-driven organisation to support evidence-based health and social care. With your help we are building on ...
Source: Cochrane News and Events - December 20, 2022 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Corticosteroid Injections May Worsen Knee OA Progression Corticosteroid Injections May Worsen Knee OA Progression
Corticosteroid knee injections appear to make knee osteoarthritis worse, and hyaluronic acid injections may be safer, two research teams report.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 19, 2022 Category: Internal Medicine Tags: Rheumatology News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Alembic gets USFDA nod for generic skin treatment cream
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Desonide Cream, 0.05 per cent, of Padagis US LLC. Desonide Cream, 0.05 per cent, is a low-potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 9, 2022 Category: Pharmaceuticals Source Type: news
RSNA: Corticosteroid Injections Appear to Worsen Knee Osteoarthritis
WEDNESDAY, Nov. 30, 2022 -- Corticosteroid injections seem to be associated with progression of knee osteoarthritis (OA), according to two studies presented at the annual meeting of the Radiological Society of North America, held from Nov. 27 to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2022 Category: Pharmaceuticals Source Type: news
Do Steroid Injections Worsen Arthritic Knees?
WEDNESDAY, Nov. 30, 2022 -- Corticosteroid injections to relieve pain in patients with knee osteoarthritis could actually be setting them back.
Two new studies have discovered that, despite the temporary relief of symptoms, the injections were... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 30, 2022 Category: General Medicine Source Type: news
Systemic corticosteroids for the treatment of COVID19: Equityrelated analyses and update on evidence, Cochrane Library
Authors ' conclusions Systemic corticosteroids probably slightly reduce all ‐cause mortality up to 30 days in people hospitalised because of symptomatic COVID‐19, while the evidence is very uncertain about the effect on all‐cause mortality up to 120 days. For younger people (under 70 years of age) there was a potential advantage, as well as for Black, Asian, or people of a minority ethnic group; further subgroup analyses showed no relevant effects. Evidence related to the most effective type, dose, or timing of systemic corticosteroids remains immature. Currently, there is no evidence on asymptomatic or mild disease ...
Source: Current Awareness Service for Health (CASH) - November 30, 2022 Category: Consumer Health News Source Type: news
Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19, DHSC (updated 29th November 2022)
Published policy has been updated following recommendations of the updated WHO clinical guideline. An IL-6 inhibitor may be administered in combination with baricitinib (as well as corticosteroids, unless contraindicated) as per clinical judgement in severe or critical COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 30, 2022 Category: Consumer Health News Source Type: news
